|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-8-1
|
|
pubmed:abstractText |
The selection of effective schedules of treatment for metastatic non-small cell lung cancer still remains a challenge for the oncologist. The present multicentric phase II study was designed in order to investigate the activity and safety of the combination of weekly paclitaxel and celecoxib as second-line treatment for non-small cell lung cancer. As a secondary endpoint, the possible correlation of biomarkers with objective response was investigated in a subset of patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1528-9117
|
|
pubmed:author |
pubmed-author:AvalloneAntonioA,
pubmed-author:BonginelliPaolaP,
pubmed-author:ComellaGiuseppeG,
pubmed-author:GamucciTeresaT,
pubmed-author:GaspariniGiampietroG,
pubmed-author:GattusoDomenicoD,
pubmed-author:GionMassimoM,
pubmed-author:Lo VulloSalvatoreS,
pubmed-author:MansuetoGiovanniG,
pubmed-author:MarianiLuigiL,
pubmed-author:MeoSabrinaS,
pubmed-author:StaniSimonetta ChiaraSC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
209-16
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16053664-Administration, Oral,
pubmed-meshheading:16053664-Adult,
pubmed-meshheading:16053664-Aged,
pubmed-meshheading:16053664-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:16053664-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16053664-Combined Modality Therapy,
pubmed-meshheading:16053664-Cyclooxygenase Inhibitors,
pubmed-meshheading:16053664-Drug Administration Schedule,
pubmed-meshheading:16053664-Drug Therapy, Combination,
pubmed-meshheading:16053664-Female,
pubmed-meshheading:16053664-Humans,
pubmed-meshheading:16053664-Infusions, Intravenous,
pubmed-meshheading:16053664-Lung Neoplasms,
pubmed-meshheading:16053664-Male,
pubmed-meshheading:16053664-Middle Aged,
pubmed-meshheading:16053664-Paclitaxel,
pubmed-meshheading:16053664-Pyrazoles,
pubmed-meshheading:16053664-Sulfonamides,
pubmed-meshheading:16053664-Survival Analysis,
pubmed-meshheading:16053664-Treatment Outcome,
pubmed-meshheading:16053664-Tumor Markers, Biological,
pubmed-meshheading:16053664-Vascular Endothelial Growth Factor A
|
|
pubmed:articleTitle |
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
|
|
pubmed:affiliation |
Medical Oncology Unit, Azienda Ospedaliera, San Filippo Neri, Rome. gasparini.oncology@tiscalinet.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
